摘要
激肽释放酶(Kallikrein,KLK)是丝氨酸蛋白酶家族的一员,多种KLK,尤其是KLK7在人类表皮中大量表达,为维持皮肤的正常生理活动发挥着重要作用。研究表明,特应性皮炎(atopic dermatitis,AD)作为一种与遗传有密切关系的炎性皮肤类疾病,与表皮中KLK7的活性的增加有着紧密的联系。特应性皮炎目前尚无根治的办法,KLK7是一种潜在的治疗特应性皮炎的药物靶标,因此研发KLK7的抑制剂将有助于为特应性皮炎等炎性皮肤病的临床治疗提供新的思路。
Kallikrein（KLK） is a member of serine protease family. A variety of KLKs, especially KLK7, are highly expressed in human skin epidermis and play an important role in maintenance of normal physiological activity of the skin. The atopic dermatitis（AD） is a heredity-related inflammatory skin disease and there is no radical solution for AD at present. Recent studies have shown that increased activity of KLK7 in the epidermis is closely associated with AD and is a potential drug target for this disease, thus the development of KLK7 inhibitors will provide us a novel strategy for the treatment of AD and AD-like skin diseases.
出处
《生命的化学》
CAS
CSCD
2015年第6期715-720,共6页
Chemistry of Life
基金
肿瘤微环境与免疫治疗湖北省重点实验室(三峡大学)开放基金(2015kzl04)
